Published in Gastroenterology on February 21, 2007
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother (2010) 2.28
Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol (2012) 2.24
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother (2008) 2.22
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology (2010) 1.96
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol (2012) 1.85
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One (2009) 1.70
A perspective on modelling hepatitis C virus infection. J Viral Hepat (2010) 1.67
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother (2007) 1.66
Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A (2010) 1.65
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother (2007) 1.59
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57
Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother (2008) 1.57
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother (2008) 1.56
Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. J Infect Dis (2009) 1.51
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol (2012) 1.50
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother (2012) 1.48
Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use. Dig Dis Sci (2011) 1.47
Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother (2009) 1.43
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol (2010) 1.42
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother (2010) 1.42
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis (2011) 1.33
Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One (2009) 1.32
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog (2012) 1.30
Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. J Clin Microbiol (2011) 1.25
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology (2012) 1.24
Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol (2009) 1.22
Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol (2007) 1.21
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc (2011) 1.20
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother (2014) 1.20
Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. J Clin Microbiol (2012) 1.19
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19
Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol (2010) 1.18
Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol (2010) 1.17
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother (2012) 1.16
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. Virol J (2012) 1.16
Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr Opin Pharmacol (2009) 1.14
The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol (2009) 1.14
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis (2012) 1.13
Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol (2013) 1.12
Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant (2013) 1.11
Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol (2011) 1.10
Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol (2012) 1.10
In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother (2007) 1.09
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother (2011) 1.08
Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J Virol (2008) 1.08
Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res (2009) 1.07
Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. Curr Hepat Rep (2011) 1.06
Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother (2011) 1.06
Dengue Virus Evolution under a Host-Targeted Antiviral. J Virol (2015) 1.05
Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem (2009) 1.04
Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother (2009) 1.03
Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol (2012) 1.03
Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol (2010) 1.02
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother (2012) 1.01
Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol (2008) 1.00
Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Antimicrob Agents Chemother (2012) 1.00
Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother (2008) 0.99
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol (2012) 0.98
Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol (2013) 0.97
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM (2012) 0.97
New hepatitis C therapies in clinical development. Eur J Med Res (2011) 0.96
Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2011) 0.96
Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother (2011) 0.95
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag (2012) 0.95
Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob Agents Chemother (2011) 0.95
New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol (2010) 0.94
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study. Antimicrob Agents Chemother (2013) 0.93
Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol (2015) 0.92
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob Agents Chemother (2010) 0.92
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother (2008) 0.92
Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat (2011) 0.91
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol (2015) 0.91
Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. World J Virol (2013) 0.91
Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother (2011) 0.91
Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors. Mem Inst Oswaldo Cruz (2013) 0.90
Hepatitis C Viral Kinetics in Special Populations. Curr Hepat Rep (2008) 0.90
Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therap Adv Gastroenterol (2009) 0.89
Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir. PLoS One (2012) 0.89
Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C. Antivir Ther (2014) 0.89
Evolutionary rescue: linking theory for conservation and medicine. Evol Appl (2014) 0.89
Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction. Antimicrob Agents Chemother (2012) 0.89
In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother (2013) 0.89
Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses (2015) 0.89
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol (2016) 0.88
Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep (2016) 0.88
Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol (2012) 0.88
Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol (2011) 0.88
The Future of HCV Therapy: NS4B as an Antiviral Target. Viruses (2010) 0.87
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
The zebrafish reference genome sequence and its relationship to the human genome. Nature (2013) 8.52
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron (2005) 4.87
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol (2007) 4.70
ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc Natl Acad Sci U S A (2009) 4.46
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Hrs regulates endosome membrane invagination and tyrosine kinase receptor signaling in Drosophila. Cell (2002) 3.72
Genetic analysis of cavefish reveals molecular convergence in the evolution of albinism. Nat Genet (2005) 3.66
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol (2008) 3.43
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology (2003) 3.09
The v-ATPase V0 subunit a1 is required for a late step in synaptic vesicle exocytosis in Drosophila. Cell (2005) 3.05
Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development (2004) 3.03
Mitoferrin is essential for erythroid iron assimilation. Nature (2006) 2.99
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Synaptojanin is recruited by endophilin to promote synaptic vesicle uncoating. Neuron (2003) 2.96
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89
The cdx genes and retinoic acid control the positioning and segmentation of the zebrafish pronephros. PLoS Genet (2007) 2.85
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
RNA-mediated epigenetic programming of a genome-rearrangement pathway. Nature (2007) 2.79
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 2.78
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. PLoS Biol (2006) 2.70
Manipulating surface states in topological insulator nanoribbons. Nat Nanotechnol (2011) 2.70
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis (2008) 2.69
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Occult hepatitis C: how convincing are the current data? Hepatology (2009) 2.49
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
Endophilin mutations block clathrin-mediated endocytosis but not neurotransmitter release. Cell (2002) 2.43
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother (2006) 2.42
Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol (2011) 2.40
The zinc finger transcription factor Gfi1, implicated in lymphomagenesis, is required for inner ear hair cell differentiation and survival. Development (2003) 2.38
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology (2007) 2.37
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology (2009) 2.35
Mutations in Drosophila sec15 reveal a function in neuronal targeting for a subset of exocyst components. Neuron (2005) 2.33
TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell (2010) 2.33
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis (2005) 2.33
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem (2004) 2.25
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci U S A (2005) 2.19
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Mutant-specific gene programs in the zebrafish. Blood (2005) 2.15
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
The Oxytricha trifallax macronuclear genome: a complex eukaryotic genome with 16,000 tiny chromosomes. PLoS Biol (2013) 2.08
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol (2013) 2.08
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis (2006) 2.06
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect Immun (2002) 2.02